A Call for ‘Naming and Shaming’ of ‘Unhelpful’ Cannabis Drug Firms in the U.K.

July 11, 2019

Proposals to name and shame businesses that fail to provide cannabis drugs for use in U.K. clinical trials have been made by Members of Parliament.

After months of interviews and weighing-up reams of evidence The House of Commons Health and Social Care Committee has issued its latest report; ‘Drugs policy: medicinal cannabis’. It concludes that the main reason so few NHS cannabis prescriptions have been made in the U.K. – believed to be no more than 10 – is that clinicians fear they will be putting their jobs on the line by prescribing cannabis medication.

According to the NHS England, “As with prescribing any other unlicensed medicine, it is a clinical decision to determine the most appropriate medication or course of treatment to prescribe for a patient, having taken into account the patient, the clinical condition, the clinical evidence of efficacy and safety and the suitability of licensed medicines.”

However the problem in the U.K. is such special drugs are subject to stringent guidelines. The committee report elaborates: “Doctors must be satisfied that there is a sufficient evidence base for prescribing the unlicensed product.

“If there is an insufficient evidence base, doctors are reluctant to prescribe knowing that they are taking personal responsibility for doing so and that there could be serious professional and legal consequences if there are adverse outcomes for their patient.”

The report goes on to say it believes more research is needed into cannabis prescriptions in the U.K. It says the Government and industry should work to further the evidence base in order to improve the confidence of doctors and allow more products to be licensed.

But it says one of the barriers to research is that industry is not always prepared to supply products for research trials. “We heard throughout our inquiry that some pharmaceutical companies were not willing to provide their product for trial,” the report says.

One senior clinician told the committee she believes some companies do not feel the ‘need to do the trials because it is just going to be prescribed and therefore it is going to be okay’.

It concludes that some such companies should be sanctioned adding: “The Department should not be afraid to ‘name and shame’ companies who are not doing all they can to make their products available for research.” However, this approach has been criticized by the cannabis industry with Hari Guliani, Chief Operating Officer of London firm Grow Biotech saying:

“We welcome the recommendation to increase engagement with patients and the public on this and the focus on helping families of children with intractable epilepsy. 

“However, the risk of ‘naming and shaming’ companies who do not support all forms of research is likely to dissuade companies from investing in the UK, compared with other jurisdictions. Instead, it would be helpful to encourage these companies to develop a greater understanding in the UK.”

The post A Call for ‘Naming and Shaming’ of ‘Unhelpful’ Cannabis Drug Firms in the U.K. appeared first on Cannadelics.

Also in Education

Missouri to Vote on Recreational Cannabis, Expungement Amendment

August 15, 2022


Missouri to Vote on Recreational Cannabis, Expungement Amendment by Aron Vaughan

Nov. 8, Missouri residents will have the opportunity to vote on legalization of adult-use cannabis.  Missouri passed a constitutional amendment for medical cannabis in 2018 and advocates are looking to build on the momentum in the state.  Amendment 3, the Marijuana Legalization Initiative, is on the ballot in Missouri as an initiated constitutional amendment. If […]

A link to your site, with your site's name and description as anchor text.

Continue Reading

Cannabis Europa 2022, lifting your head to see the horizon

August 15, 2022

The location of Cannabis Europe is a fascinating echo of an industry that has seen better times in the UK. Old Billingsgate market was set up in 1850 and ran at its location until 1982, the UK’s famous fish market then moved to new locations as the fishing industry declined.  The cannabis industry by any …

Continue Reading

2022 Cannabis Ballot Measures: Up to Six States Voting for Recreational

August 13, 2022

They’re not there yet, and they might not get there, but this coming November, at least three states, (and possibly six), are putting it up to voters in yet more cannabis ballot measures for recreational legalizations. Will we get up to 25 legal states by the end of elections? 2022 elections are going to be […]

The post 2022 Cannabis Ballot Measures: Up to Six States Voting for Recreational appeared first on Cannadelics.

Continue Reading